Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease

被引：14
|
作者：
Josting, A
Engert, A
Diehl, V
Canellos, GP
机构：
[1] Univ Hosp Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
[2] German Hodgkin Lymphoma Study Grp, Cologne, Germany
[3] Dana Faber Canc Inst, Dept Adult Oncol, Boston, MA USA
来源：
ANNALS OF ONCOLOGY | 2002年 / 13卷
关键词：
D O I：
10.1093/annonc/13.S1.112
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：112 / 116
页数：5
相关论文
共 50 条
  • [21] Primary Non-Hodgkin's Lymphoma of the nasopharynx: Prognostic factors and outcome of 113 Indian patients.
    Bahl, G.
    Laskar, S.
    Muckaden, M. A.
    De, S.
    Nair, R.
    Gupta, S.
    Bakshi, A.
    Gujral, S.
    Shrivastava, S. K.
    Dinshaw, K. A.
    RADIOTHERAPY AND ONCOLOGY, 2006, 81 : S401 - S402
  • [22] Hodgkin disease: prognostic factors and treatment strategies
    Josting, A
    Wolf, J
    Diehl, V
    CURRENT OPINION IN ONCOLOGY, 2000, 12 (05) : 403 - 411
  • [23] The disappearance of prognostic factors in Hodgkin's disease
    Hasenclever, D
    ANNALS OF ONCOLOGY, 2002, 13 : 75 - 78
  • [24] Prognostic factors for Hodgkin's disease.
    Petra, F
    Repousis, P
    Kourtis, G
    Sirseloudis, D
    BLOOD, 2002, 100 (11) : 291B - 291B
  • [25] Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma
    Chau, I
    Harries, M
    Cunningham, D
    Hill, M
    Ross, PJ
    Archer, CD
    Norman, AR
    Wotherspoon, A
    Koh, DM
    Gill, K
    Uzzell, M
    Prior, Y
    Catovsky, D
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (06) : 970 - 977
  • [26] Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease
    Milosevic, V.
    Petrovic, M.
    Mihaljevic, B.
    Jankovic, S.
    Nedeljkov, R. Jancic
    Boskovic, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 451 - 451
  • [27] Prognostic factors and treatment outcome in non-Hodgkin's lymphoma of Waldeyer's ring
    Harabuchi, Y
    Tsubota, H
    Ohguro, S
    Himi, T
    Asakura, K
    Kataura, A
    Ohuchi, A
    Hareyama, M
    ACTA ONCOLOGICA, 1997, 36 (04) : 413 - 420
  • [28] Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease
    Aurer, I
    Radman, I
    Nemet, D
    Zupancic-Salek, S
    Bogdanic, V
    Mrsic, M
    Sertic, D
    Labar, B
    ONKOLOGIE, 2005, 28 (11): : 567 - 571
  • [29] Prognostic factors in primary extranodal non-Hodgkin's lymphoma patients
    Poddubnaya, I
    Balakireva, Y
    Osmanov, D
    ANNALS OF ONCOLOGY, 2005, 16 : 160 - 160
  • [30] Clinical outcome and prognostic factors evaluation in adolescent patients with relapsed or refractory Hodgkin's lymphoma receiving autologous stem cell transplant
    Akhtar, Saad
    El Weshi, Amr
    Rahal, Mohemed
    Abdelsalam, Mahmoud
    Janabi, Iman
    Hamed, Husseini
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 425 - 425
12345